Introduction
Epilepsy is a common, serious, and treatable neurological disorder. Despite significant advances in the therapy of epilepsy over recent decades, about one third of patients with newly diagnosed epilepsy will become refractory to treatment, with their seizures impacting upon day-to-day activity, social well-being, independence, economic output and quality of life. [1] [2] [3] [4] The mechanisms underlying the development of drug-resistance in epilepsy are complex and, at this time, not fully understood. 5 Drug-resistance depends on a number of clinical aspects including aetiology, early age at seizure onset, type of epileptic syndrome and seizure, structural brain abnormalities or lesions, or abnormal electroencephalographic findings. [1] [2] [3] [4] Furthermore, drug-resistance may depend on genetic and acquired factors affecting pharmacokinetics or pharmacodynamics of AEDs. Genetic factors may reduce serum drug concentrations either by reducing absorption or by increasing elimination and/or the access of AEDs to the epileptic focus in the central nervous system (CNS).
In addition, genetic factors may be responsible of changes in AED targets reducing the response to drugs. 3, 6, 7 Many AEDs are metabolised by the cytochrome P450 (CYP) and uridin diphosphate glucuronosyl transferase (UGT) superfamilies. CYP2C9 contributes to the metabolism of phenytoin and valproic acid; CYP2C19 contributes to the metabolism of phenytoin, diazepam and phenobarbital. [7] [8] [9] [10] Two polymorphisms of CYP2C9
Epilepsy drug-resistance may depend on the metabolism of antiepileptic drugs (AEDs), transport to the epileptic focus and/or target sensitivity. Furthermore, drug response depends on multiple characteristics of the patient, the epilepsy, and the antiepileptic drugs used.
We have investigated the association between polymorphisms related to antiepileptic drug metabolism (CYP2C9, CYP2C19, and UGT), transport (ABCB1), and targets (SCN1A) both in a crude analysis and after adjusting by clinical factors associated with drug-resistance, and stratifying by patient age or aetiology of epilepsy.
Caucasian outpatients (N = 289), children (N = 80) and adolescent-adults (N = 209), with idiopathic (N = 69), cryptogenic (N = 97) or symptomatic epilepsies (N = 123) were selected when they had either drug-resistance (with at least four seizures over the previous year after treatment with more than three appropriate AEDs at appropriate doses) or drug responsiveness (without seizures for at least a year). Samples were genotyped by allelic discrimination using TaqMan probes.
No significant association between polymorphisms and drug-resistance was found either in the crude analysis or in the adjusted analysis. However, adults with the ABCB1_3435TT or 2677TT genotypes had a lower risk of drug-resistance than those with the CC or the GG genotypes. Furthermore, patients with symptomatic epilepsies with the ABCB1_3435CT or TT genotypes had a lower risk of drug-resistance than those with the CC genotype. An opposite but insignificant tendency was found in children and in idiopathic epilepsies.
Although replication studies will be needed to confirm our results, they suggest that stratification by patient age and by the aetiology of epilepsy could contribute to unmask the association between ABCB1 polymorphisms and drug-resistance of epilepsy.
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(*2 and *3) are known to slow down the metabolism of phenytoin to a degree that increases the risk of the neurotoxic effects of this drug among carriers of these polymorphisms, whereas the influence of CYP2C19 polymorphisms is minor. UGT2B15 participates in lorazepam metabolism. 17 However, the functional significance of UGT2B7 polymorphisms is unclear. 18 In one study, AUCs of valproate increased with the number of UGT2B7*2 alleles, but the difference was insignificant.
14 Drug-resistance may also be caused because sufficient intraparenchymal AED concentrations are not attained in the epileptic focus by an enhanced function of multidrug transporters or because target sites are structurally and/or functionally modified and become less responsive to AEDs. 5, 19, 20 In 2003, Siddiqui et al. reported the 3435C>T polymorphism in the ABCB1 gene as being associated with resistance to multiple AEDs. Patients with multidrug-resistant epilepsy were significantly more likely to have CC than TT genotype. 21 Because the CC genotype has been associated with increased expression of intestinal P-glycoprotein, 22 the data of Siddiqui et al. 21 suggested that CC genotype may be associated with increased expression and functionality of P-glycoprotein also at the blood-brain barrier, leading to reduced AED concentrations at their brain targets. Several studies have confirmed the association of ABCB1_3435C>T or ABCB1_2677G>T polymorphisms with drug-resistance, but other studies could not find it. 7 In a recent meta-analysis, an association between ABCB1 polymorphisms and antiepileptic drugs response was not found. 23 Differences in methodology and patients' recruitment from one study to another may influence the results. 7 Most studies were performed in multiple types of epilepsy and with multiple AEDs, but no attempt was made to separate children from adults or idiopathic from cryptogenic and symptomatic epilepsies despite there being important differences in drug-resistance and type of antiepileptic drugs used in each subgroup. With respect to AED targets, the inhibition of voltage-gated sodium channels is the main mechanism of most AEDs, and mutations in SCN1A gene have been associated with different types of genetic epilepsies. 6 Furthermore, SCN1A_IVS5N+5G>A
polymorphism has been associated with the maximum tolerated dose of phenytoin and carbamazepine. 24, 25 The primary goals of this study were the following: (i) to analyze the association between several single nucleotide polymorphisms (SNPs) of the CYP2C9, CYP2C19, UGT2B7, ABCB1, and SCN1A genes by bivariate analysis and (ii) to analyze these associations taking into account some factors related with the patient and his/her epilepsy by multivariate analysis. The secondary goal was to investigate these associations stratifying patients by patient age and epilepsy aetiology.
Materials and methods
The protocol for this observational study was approved by the Regional Ethics Committee and it was carried out in accordance with The Code of Ethics of the World Medical Association (Declaration of Helsinki) for experiments involving humans.
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Written informed consent was obtained from patients or from their parents or legal guardians.
The study was carried out on 289 outpatients attending the Neuropediatrics and Neurology Services at the Marqué s de Valdecilla University Hospital. These Services are the neurological reference Services attending most epileptic patients in Cantabria, an autonomous community at the north of Spain with about 600,000 inhabitants.
Patients, all Caucasians, were included when they had an established clinical diagnosis of epilepsy (defined by the occurrence of two or more unprovoked seizures) confirmed by an electroencephalogram examination by an expert. Furthermore, patients were included when they had either drug-resistant or drug-responsive epilepsy according to the following definitions and criteria. Drug-resistance was defined as the occurrence of at least four seizures over the year before recruitment with trials of more than three appropriate AEDs at maximal tolerated doses, which were established on the basis of the occurrence of clinical side effects at supra-maximal doses or trough serum concentrations at the higher limit of the optimal interval. Only the recognized, more specific drugs for a syndrome were considered appropriate. Drug responsiveness was defined as complete freedom from seizures for at least a year, up to the date of the last follow-up visit, in patients with epilepsy treated with AEDs.
Medical history of each patient was revised by the two neuropediatricians and the two neurologists participating in the study. Data collected before genotyping on a specific form were the following: patient age and gender, family history of epilepsy (yes/ no) and/or febrile seizures (yes/no), past medical history of troubles during pregnancy, labour or post-labour (6 categories), electroencephalographic location of paroxysmal activity (14 categories), age at the onset of epilepsy, type of seizures (generalized or partial), aetiology of the epilepsy (idiopathic, cryptogenic or symptomatic), and presence of neurological alterations (yes/no). Symptomatic epilepsies were dues to the following causes according to the classification of Engel Table 1 . Predeveloped Taqman assay reagents for allelic discrimination were used for all SNPs except the one for ABCB1_2677G>T, which was developed in our laboratory. Fifty nanograms of DNA were used and the manufacturer's instructions were followed. Polymerase chain reaction amplification consisted of an initial denaturation for 5 min at 95 8C, followed by 50 cycles of denaturation at 92 8C for 1 min, annealing at 57 8C for 50 s and an extension at 72 8C for 1 min. PCR reactions were carried out in a Bio-Rad iCycler thermocycler (Bio-Rad, Hercules, California, USA). Samples remained at 4 8C until visualization. Visualization of fluorescence in each sample at the end of the reaction was performed by the Stratagene MX3000P QPCR System (Agilent Technologies Company, La Jolla, CA, USA), using the MxProQPCR software. Genotyping was performed in a blinded fashion with respect to the drugresistance condition of the patient. ABCB1_2677G>T genotypes were confirmed by an alternative method using the polymerase chain reaction-restriction fragment length polymorphism method described by Cascorbi et al. 28 To evaluate the influence of patient age, patients were divided into children ( 12 years) and adolescent-adults (>12 years) subgroups. To evaluate the influence of the aetiology of epilepsy, patients were divided into idiopathic, cryptogenic and symptomatic epilepsy subgroups. The statistical analysis was carried out using the SPSS for Windows version 15.0 software (SPSS Inc., Chicago, IL, USA) and the SNPStats software. 29 SPSS was used to compare genotypic frequencies between drug-responsive and drug-resistant patients, and to analyze the association between each polymorphism and drug-resistance by binary logistic regression between both in a bivariate analysis without including clinical factors, and in a multivariate analysis taking into account clinical factors. SNPStats was used to compare observed and expected frequencies by means of the Hardy-Weinberg test, and to analyze the interaction between each polymorphism and covariates. A two-sided test (P < 0.05) was considered significant throughout.
Results
Characteristics of drug-sensitive and drug-resistant patients are shown in Table 2 . Significant differences between drug-responsive and drug-resistant patients were found in past medical history (P = 0.016), type of seizure (P < 0.001), age at the onset of epilepsy (P < 0.001), aetiology of epilepsy (P < 0 .001), and neurological alterations (P < 0.001).
Hardy-Weinberg equilibrium was observed for all the polymorphisms studied except for ABCB1_2677G>T (P = 0.007). No significant association between drug-resistance and each polymorphism was observed either in the bivariate analysis (without including clinical factors) or the multivariate analysis in which clinical factors were taken into account by means of logistic regression (Table 3) .
However, significant associations between ABCB1 polymorphisms and drug-resistance were found when patients were stratified by patient age or aetiology of epilepsy. When patients were stratified by patient age, a significant association was observed between ABCB1_3435C>T and ABCB1_2677G>T polymorphisms and drug-resistance in adults, but not in children. In adults, frequencies of ABCB1_3435TT and ABCB1_2677TT genotypes were significantly lower than those of ABCB1_3435CC or ABCB1_2677GG genotypes (P = 0.019 and P = 0.03, respectively). The crude odds ratios indicated a lower risk of drug-resistance in the patients with the genotype TT than in those with the genotype CC (OR: 0.40, 95%CI: 0.19-0.86) or GG (OR: 0.41, 95%CI: 0.18-0.92). In children, an opposite tendency was observed, suggesting a higher risk in patients with genotypes TT than CC or GG, but statistical significance was not achieved (Table 4 ). The interaction between the patient age factor and ABCB1 polymorphisms was significant both for ABCB1_3435C>T (P = 0.033) and for ABCB1_2677G>T (P = 0.021).
With respect to the aetiology of epilepsy, a significant association between ABCB1_3435C>T polymorphism and drugresistance was to be found in the subgroup of patients with symptomatic epilepsy (P = 0.011) but not in those with idiopathic or cryptogenic epilepsies. In the subgroup of patients with symptomatic epilepsy, frequency of ABCB1_3435TT genotype was significantly lower than that of CC genotype in drug-resistant patients (P = 0.003). The crude odds ratio indicated a lower risk of drug-resistance in the patients with the genotype CT or TT than in those with the genotype CC (OR: 0.39, 95%CI: 0.16-0.94 and OR: 0.20, 95%CI: 0.07-0.58, respectively). In contrast, a tendency to a higher risk in patients with genotypes CT or TT than CC was observed in patients with idiopathic epilepsies, but differences were not statistically significant ( Table 5 ). The interaction between the epilepsy aetiology factor and the ABCB1_3435C>T polymorphism was significant (P = 0.005).
Discussion
Mechanisms of epilepsy drug-resistance are complex and multifactorial and, therefore, it may be difficult to find a significant association with a SNP. In fact, when all patients were analyzed as a whole, significant associations between the SNPs included in our study and epilepsy drug-resistance were not found in the bivariate analysis in which demographic and clinical factors were not considered.
Our hypothesis was that the association of polymorphisms with drug-resistance could be masked by the unequal presence of factors known to influence drug-resistance of epilepsy. Therefore, we consider necessary to analyze the association between polymorphisms and drug-resistance taking into account and stratifying patients by clinical factors that influence drugresistance of epilepsy. In fact, in our study there was a significant association of drug-resistance with covariates such as past medical history, type of seizures, age at the onset of epilepsy, aetiology of epilepsy or neurological alterations. However, when the association between polymorphisms and drug-resistance was adjusted by clinical factors by means of logistic regression, a significant association between the SNPs studied and drug-resistance was neither found.
Studies investigating the association between polymorphisms and drug-resistance adjusting by clinical factors are scarce. In the study of Seo et al. 30 in Japanese patients, in which the risk of drugresistance was higher in patients of low age at the onset of epilepsy, in those with generalized seizures, and in those with cryptogenic and symptomatic epilepsies, a significant but opposite association was found because ABCB1_3435TT frequency was higher in drug-resistant patients. In contrast, in another study in Chinese patients, a significant association between ABCB1_3435C>T and ABCB1_2677G>T polymorphisms and drug-resistance was found when the odds ratio was adjusted by the presence of mesial temporal lobe epilepsy. 31 In a recent study, the intronic polymorphism rs3789243 and the coding polymorphism 2677G/T/A, and haplotypes containing them, were associated with drug-resistance, and the 2677G/T/A genotypes remained significantly associated with drug-resistance after multiple logistic regression and correction for multiple comparisons. 32 Whether differences in results between studies depend on methodological aspects, chance or ethnic factors remains to be clarified. With respect to the other SNPs included in our study, we have not found any study investigating their association with epilepsy P: significance of Wald statistic and odds ratio by logistic regression (bivariate analysis). P 0 : significance of Wald statistic and odds ratio by logistic regression including as factors patient age groups, gender, family history of epilepsy, family history of febrile seizures, past medical history, EEG location of paroxysmal activity, type of seizures, type of epilepsy, aetiology of epilepsy, and presence of neurological alterations, and as covariate the age at the onset of epilepsy.
Table 4
Genotypic frequencies and drug-resistance odds ratios for each genotype in children and adults for ABCB1_3435C>T and ABCB1_2677G>T polymorphisms. drug-resistance, with the exception of a recent study in which, after excluding patients with febrile convulsions, heterozygous CYP2C8*4 and CYP2C9*3 were underrepresented among nonresponder patients with epilepsy. 33 The lack of association between the SNPs included in our study and drug-resistance may be attributed to several factors. Firstly, the sample of our study may be not large enough, and therefore, the power of the study may be insufficient to detect a significant association. Perhaps, it could be demonstrated in a larger study. Secondly, some polymorphisms such as those related with CYP2C9, CYP2C19 and UGT2B7 are associated with the metabolism of some specific AEDs but not with others. Our study was not designed to analyze the association between polymorphisms and drugresistance in patients treated with a specific AED. The association between CYP2C9, CYP2C19 and drug-resistance should better be studied in patients treated with phenytoin, valproate or phenobarbital, and the association with UGT2B7 in patients treated with valproate or lamotrigine. Thirdly, polymorphisms affecting AED metabolism are expected to exert an influence on serum concentrations of AEDs and to produce insufficient concentrations, but in our study serum concentrations of AEDs were monitorized and maintained into the optimal range.
However, when patients were stratified by patient age or aetiology of epilepsy a significant association between ABCB1 SNPs studied and drug-resistance was found in some subgroups. With regard to patient age, a lower risk of drug-resistance was observed in patients with the 3435TT or 2677TT genotypes than in those with the 3435CC or the 2677GG genotypes in adults but not in children. With regard to epilepsy aetiology, the risk of drugresistance was lower in patients with the 3435CT or TT genotypes than in those with the CC genotype in patients with symptomatic epilepsies but not in those with idiopathic or cryptogenic epilepsies. These results have a biological plausibility. First, because several AEDs frequently used in the treatment of epilepsies are substrates of P-glycoprotein both in rodents (gabapentin, lamotrigine, phenobarbital, phenytoin, and topiramate) and humans (phenytoin, phenobarbital, lamotrigina, and levetiracetam). 34, 35 Data on carbamazepine and levetiracetam are not clear and valproic acid does not seem to be a substrate of Pglycoprotein. [35] [36] [37] [38] Second, because some of these AEDs such as phenytoin and phenobarbital are more frequently used in adults than in children and in symptomatic epilepsies than in idiopathic epilepsies, whereas valproate is more frequently used in children and in idiopathic epilepsies. Furthermore, because some antiepileptic drugs are inhibitors of P-glycoprotein (in decreasing order phenytoin > carbamazepine > lamotrigine > phenobarbital > valproic acid, levetiracetam, gabapentin) and because the ABCB1 polymorphisms influence on this inhibitory effect, the intracellular concentration of the P-glycoprotein substrates will depend on ABCB1 polymorphisms and on the combination of antiepileptic drugs (substrates and inhibitors) used.
Third, because P-glycoprotein is overexpressed in patients with symptomatic epilepsies such as tumours, dysplasias and hippocampal sclerosis. 39 Although the influence of ABCB1 polymorphisms on brain expression of P-glycoprotein is controversial because of the described lack of influence on ABCB1 mRNA and protein expression, 40, 41 it has been suggested that an important reduction in the access of AEDs to the CNS could be observed in patients overexpressing this protein by the combined effect of genetic factors and the own symptomatic epilepsy. 7 The association of ABCB1_3435C>T polymorphism with drugresistance of epilepsy has been the most studied one, but there is disagreement in the results. 7 After the initial study of Siddiqui et al. 21 in which an increased prevalence of the ABCB1_3435CC genotype was reported in patients with drug-resistant epilepsy, several studies in patients from different ethnicities have confirmed an association of both ABCB1_3435C>T SNP and the common ABCB1_3435C>T, ABCB1_2677G>T, and ABCB1_1236C>T haplotype with drug-resistance. 31, [42] [43] [44] [45] In contrast, in two studies in nonCaucasian patients, there was found to be the opposite association with a higher frequency of TT genotypes in patients with drugresistant epilepsy than in those with drug-responsive epilepsy. 30, 46 Other studies in either Caucasians and non-Caucasians patients were not able to demonstrate an association between ABCB1 polymorphisms and drug-resistance. 33, [47] [48] [49] [50] [51] [52] [53] [54] [55] [56] [57] Differences in results between studies have been attributed to phenotype definition (i.e., definition of resistance versus response to AEDs, inadequate power, potential confounding by comorbidity and comedication, population substructure, genotyping error, overlap in substrate specificity between P-glycoprotein and other drug efflux transporters, and inclusion of AEDs that might not be Pglycoprotein substrates). 7, 51 Most of these studies have been performed in patients treated with multiple AEDs. However, in studies performed with one AED, an association between ABCB1_3435C>T polymorphism and drugresistance was found in patients treated with phenytoin 45 or phenobarbital, 58 whereas in those with carbamazepine an opposite association 30 or non-association 52 was found.
Regarding patient age, children are more frequently treated with valproate and carbamazepine, whereas adults are more frequently treated with phenytoin or phenobarbital. Therefore, an Table 5 Genotypic frequencies, significance of the association between ABCB1_3435C>T polymorphism and drug-resistance and odds ratios in patients suffering from idiopathic, cryptogenic or symptomatic epilepsies. association between ABCB1 polymorphisms and drug-resistance might be better expected in adults than in children. In a recent study, the association between ABCB1, ABCC2, CYP2C8, CYP2C9, and CYP2C19 polymorphisms and drug-resistance of epilepsy was studied in Caucasian children-adolescent, either drug-sensitive or drug-resistant, and in drug-resistant adults. 33 These investigators found that carriers of the putatively low-expression ABCC2-24T variant were significantly overrepresented among non-responders children-adolescent. This surprising association was attributed to a compensatory up-regulation of ABCB1. 33 In other recent study, in south Indian patients, a significant association between ABCB1_1236C>T, ABCB1_2677G>A and ABCB1_3435C>T polymorphisms and drug-resistance of epilepsy in children-adolescent were not found, but the frequency of ABCB1_3435TT genotype was higher in drug-resistant than in drug-sensitive patients. 57 None of these studies compared the association between ABCB1 polymorphisms and drug-resistance in children under 12 years with that of adolescent-adults.
On the other hand, most of these studies were performed in patients with different types of epilepsy. 7 Our results show a significant association between ABCB1_3435C>T polymorphism and drug-resistance in patients with symptomatic epilepsy that was not found in patients with idiopathic or cryptogenic epilepsy. In the study of Tan et al., 47 in which an association between ABCB1_3435C>T polymorphism and drug-resistance of epilepsy was not found, the TT genotype was more frequent in a subgroup of patients with temporal lobe epilepsy and hippocampal sclerosis compared to those without it. Because temporal lobe epilepsy with hippocampal sclerosis is usually more drug-resistant than that without it, the authors suspected that this association was a false positive. In another study performed in Caucasian patients with temporal lobe epilepsy treated with multiple AEDs, a significant association of ABCB1_3435C>T, 2677G>T, and 1236C>T haplotype and drug-resistance was observed. 43 However, in a recent study in Turkish patients, a significant association between ABCB1_3435C>T polymorphism and drug-resistance was not found in a subgroup of patients with hippocampal sclerosis. 52 In a recent study in Korean patients with partial epilepsy an association of drug-resistance with ABCB1, ABCG2, and ABCC2 polymorphisms was not found, but stratification into idiopathic, cryptogenic and symptomatic subgroups was not carried out. 55 With respect to idiopathic epilepsies, in one study carried out in patients with idiopathic generalized epilepsy with tonic-clonic seizures treated with phenobarbital monotherapy, the ABCB1_3435CC genotype was associated with significantly lower phenobarbital levels in cerebrospinal fluid, significantly lower CSF/ plasma ratio and significantly higher seizure frequency than the CT or the TT genotype. 58 Our results do not agree with this study because we have found an opposite tendency in the subgroup of idiopathic epilepsies, but our results were not significant. Our results suggest that data obtained in children show an opposite tendency with respect to adolescent-adults and those obtained in patients with idiopathic epilepsies show an opposite tendency with respect to symptomatic epilepsies. These opposite results may have important consequences masking the association between ABCB1 polymorphisms and drug-resistance when patients are analyzed as a whole. However, we have not found a plausible explanation for this opposite tendency. Tan et al. 47 attributed the surprising overrepresentation of the ABCB1_3435TT genotype in the subgroup of patients with temporal lobe epilepsy and hippocampal sclerosis to a false positive. Ufer et al. 33 attributed the surprising overrepresentation of ABCC2-24T variant in drug-resistant children-adolescent patient to a compensatory up-regulation of ABCB1. The surprising overrepresentation of ABCB1_3435TT genotype in drug-resistant patients was found by Seo et al. 30 in drug-resistant patients taking carbamazepine. We cannot affirm if this surprising opposite tendency found in children and in idiopathic epilepsies is a chance, it is due to differences in the antiepileptic drugs used or is due to compensatory mechanisms, but it can explain the differences in the association between ABCB1 polymorphisms and drug-resistance of epilepsy found between studies. Furthermore, this association could be unmasked if patients are stratified by patient age or aetiology of epilepsy. Nevertheless, the number of children and patients with idiopathic epilepsies in our study is small and therefore, the insignificant opposite tendency observed in our study should be confirmed in a larger and more specific study.
Conclusions
In our study, carried out on children and adolescent-adults with multiple types of epilepsy and treated with multiple types of AEDs we did not find a significant association between some SNPs related with metabolism of AEDs (CYP2C9, CYP2C19, and UGT), AEDs transport (ABCB1) and one of the main AED targets (SCN1A), either in a crude analysis or adjusting by several clinical factors associated with drug-resistance of epilepsy.
However, when patients were stratified by patient age or aetiology of epilepsy a significant association was found between ABCB1 polymorphisms and drug-resistance. In the subgroup of adults, those with the ABCB1_3435TT or 2677TT genotypes had a lower risk of drug-resistance than those with the CC or the GG genotypes, respectively. Furthermore, in the subgroup of patients with symptomatic epilepsies, those with the ABCB1_3435CT or TT genotypes had a lower risk of drug-resistance than those with the CC genotype. An opposite, yet insignificant tendency was found in children and in idiopathic epilepsies. Differences between children and adults and between idiopathic and symptomatic epilepsies could be attributed to the more frequent use of phenytoin and phenobarbital (P-glycoprotein substrates) in adults and symptomatic epilepsies and the more frequent use of valproate (which is not substrate of P-glycoprotein) in children and idiopathic epilepsies.
Our results could explain differences between the association or lack of association between ABCB1 polymorphisms and epilepsy drug-resistance found in different studies due to differences in the percentage of children-adults and/or the percentage of idiopathiccryptogenic-symptomatic epilepsies in each study.
Although the stratification by patient age and aetiology of epilepsy was defined pre-analysis, the small number of subjects do not allow us to rule out that this may be a false positive association due to chance. However, the high statistical significance and the biologic plausibility of the result (the TT genotypic association confirming the a priori hypothesis) lead us to suspect that there may well be a true-positive association. Nevertheless, we consider that a large study of replication is needed to confirm our results and distinguish a true association from a false positive.
Furthermore, we consider that the best way to investigate the association between polymorphisms and drug-resistance should be in patients suffering the same type of epilepsy and/or in those treated with the same AEDs.
